@article {ANDO6207, author = {KOJI ANDO and EIJI OKI and HIROSHI SAEKI and YUTA KASAGI and YASUO TSUDA and YOKO ZAITSU and YUICHIRO NAKASHIMA and YU IMAMURA and KIPPEI OHGAKI and YOSHIHIKO MAEHARA}, title = {Number of Lymph Node Metastases May Indicate the Regimen for Adjuvant Chemotherapy in Patients with Stage III Colorectal Cancer}, volume = {35}, number = {11}, pages = {6207--6211}, year = {2015}, publisher = {International Institute of Anticancer Research}, abstract = {Background: Adjuvant chemotherapy (ACT) may prevent recurrence in patients with stage III colorectal cancer (CRC). However, only 10\% of patients benefit from ACT and no effective indicators exist to predict which patients are likely to benefit. The present study validated metastatic lymph node (MLN) number as a new indicator for ACT. Patients and Methods: We retrospectively reviewed 173 patients with stage III CRC, who were classified by Union for International Cancer Control (UICC) stage or N category, and analyzed their overall survival (OS) and disease-free survival (DFS) according to stage, number of MLNs and ACT use. Results: Among 173 patients, we found 65 with only one MLN (N1a). For N1a patients treated with ACT, the 5-year OS rate was 100\%; the 3-year DFS rate was 92.7\% for those treated with oral ACT. Conclusion: The number of MLNs is a simple indicator for ACT in patients with stage III CRC. For patients with only one MLN, oral chemotherapy is a good option.}, issn = {0250-7005}, URL = {https://ar.iiarjournals.org/content/35/11/6207}, eprint = {https://ar.iiarjournals.org/content/35/11/6207.full.pdf}, journal = {Anticancer Research} }